Recent News for HROW - Harrow Health, Inc.

Date Title
Dec 16 Is Harrow Health, Inc. (HROW) A Good Stock To Buy?
Dec 12 The Harrow Health (NASDAQ:HROW) Share Price Is Up 256% And Shareholders Are Boasting About It
Dec 11 Inventor Of "LessDrops," Surgical Eyedrop, Wins Return Of Patent From Harrow Health
Dec 10 ImprimisRx’s FDA-Registered Outsourcing Facility Issued California License
Nov 14 Harrow Health up 22% after improved fundamentals in Q3
Nov 14 IGT, OPRA, PING and SINA among midday movers
Nov 14 Kadmon Holdings leads healthcare gainers, electroCore and Jaguar Health among losers
Nov 14 Harrow Health, Inc. (HROW) CEO Mark Baum on Q3 2019 Results - Earnings Call Transcript
Nov 13 Harrow Health (HROW) Reports Q3 Loss, Misses Revenue Estimates
Nov 13 Harrow Health EPS misses by $0.21, misses on revenue
Nov 13 Harrow Health Publishes Third Quarter Letter to Stockholders
Nov 6 Earnings Preview: Harrow Health (HROW) Q3 Earnings Expected to Decline
Oct 30 Publicly traded health care company signs lease for Green Hills headquarters
Oct 28 Is Harrow Health (NASDAQ:HROW) A Risky Investment?
Oct 24 Harrow Health to Announce Third Quarter 2019 Financial Results on November 13, 2019
Oct 23 Solas BioVentures Co-Founder David Adair, M.D. Joins Mayfield Pharmaceuticals Board of Directors
Oct 8 Mayfield Pharmaceuticals to Present at the SVB Leerink New Treatments Focused on Women’s Health Conference on October 10, 2019
Oct 8 ImprimisRx to Focus on Investments in Quality at the 2019 American Academy of Ophthalmology Meeting
Sep 20 Harrow Health, Inc. (NASDAQ:HROW) Delivered A Better ROE Than Its Industry
Sep 18 The Zacks Analyst Blog Highlights: Air Industries, Chuy's, CNX Midstream Partners, Hibbett Sports and Harrow Health
Sep 17 5 Best Stocks to Buy on Dollar's Newfound Strength
Aug 27 Harrow Health to Attend Lake Street’s 3rd Annual Best Ideas Growth Conference September 12, 2019
Aug 19 Harrow Health Enters Oversold Territory
Aug 15 SHAREHOLDER ALERT: Investigation of Harrow Health Announced by Holzer & Holzer, LLC
Aug 15 Harrow Health down 22% after Q2 report absent a key disclosure

Back to the Main HROW Page...